Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Expanded Program on Immunization


Background and Definition
Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in  700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.
 
EPI ِAims at:
  1. Elevating routine vaccination coverage per district to above 95%.
  2. Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
  3. Eradicating Measles and Rubella by the end of year 2018.
 
EPI Activities:
  1. Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
  2. Continuous work to keep Lebanon certified polio-free
  3. Implementation of the RED STRATEGY to reach every child, which includes:
    1. Data on the immunization coverage for children under one year of age
    2. Data on immunization coverage in Lebanon
    3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
  4. Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination 
  5. Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
  6. Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service 
  7. Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
  8. Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.
     
    ...
    39
    ...
ATC Name B/G Ingredients Dosage Form Price
S01EA05 BGLAU G Brimonidine tartrate - 0.2% 0.2% Drops solution 638,325 L.L
S01EA05 BRIMO G Brimonidine tartrate - 0.2% 0.2% Drops solution 658,483 L.L
S01EA05 BRIMONIDINE BIOGARAN G Brimonidine tartrate - 2mg/ml 0.2% Drops solution 412,560 L.L
C01CA03 NORADRENALINE RENAUDIN G Norepinephrine tartrate - 8mg/4ml 0.2% Injectable solution 2,000,981 L.L
S01EA05 BRIMOGAN G Brimonidine tartrate - 0.2% w/v 0.2% w/v Drops solution 483,783 L.L
C05AE01 RECTOGESIC G Glyceryl trinitrate - 0.2% w/w 0.2% w/w Ointment 2,553,301 L.L
J01MA02 CIPROX G Ciprofloxacine (lactate) - 200mg/100ml 0.2%w/v Injectable solution 520,067 L.L
D07AC18 PEITEL B Prednicarbate - 0.25% 0.25% Cream 507,972 L.L
D03AX MEBO B ?-sitosterol - 0.25% 0.25% Ointment 760,615 L.L
D03AX HEALIN B G ?-sitosterol - 0.25% 0.25% Ointment 849,820 L.L
D03AX RENEBO G ?-sitosterol - 0.25% w/w 0.25% w/w Ointment 456,906 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.25mcg 0.25mcg Capsule 1,138,235 L.L
A10BJ06 OZEMPIC B Semaglutide - 0.25mg 0.25mg Injectable solution 10,927,526 L.L
L01XK04 TALZENNA B Talazoparib - 0.25mg 0.25mg Capsule 133,836,699 L.L
N05BA12 ALPRAZOLAM BIOGARAN G Alprazolam - 0.25mg 0.25mg Tablet, scored 115,570 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 3,420,079 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 21,354,452 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 21,354,452 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 3,420,079 L.L
L04AA42 MAYZENT B Siponimod - 0.25mg 0.25mg Tablet, film coated 13,899,020 L.L
L04AA42 MAYZENT B Siponimod - 0.25mg 0.25mg Tablet, film coated 108,114,165 L.L
C01AA05 LANOXIN B Digoxin - 0.25mg 0.25mg Tablet 215,015 L.L
H01CC01 ORGALUTRAN B Ganirelix - 0.25mg/0.5ml 0.25mg/0.5ml Injectable solution 2,383,977 L.L
N02CX01 APIZINE G Pizotifen - 0.25mg/5ml 0.25mg/5ml Syrup 505,541 L.L
A04AA05 ALOXI B Palonosetron HCl - 0.25mg/5ml 0.25mg/5ml Injectable solution 3,656,595 L.L
D07AC04 FLUOCINOLONE ACETONIDE G Fluocinolone acetonide - 0.25mg/g 0.25mg/g Cream 296,925 L.L
S01GX08 ZALERG G Ketotifen - 0.25mg/ml 0.25mg/ml Drops solution 446,156 L.L
A03BA01 ATROPINE I.V. 0.25 MG. G Atropine - 0.25mg/ml 0.25mg/ml Injectable solution 2,412,129 L.L
B01AC17 AGGRASTAT B Tirofiban hydrochloride monohydrate - 0.25mg/ml 0.25mg/ml Injectable concentrated solution 18,280,324 L.L
A11CC06 HIDROFEROL G Calcifediol - 0.266mg 0.266mg Capsule, soft 1,316,966 L.L
    ...
    39
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026